# Faeth Therapeutics, Inc. (FTH)

> Source: Nexqual · https://nexqual.com/FTH · data as of 2026-10-29 15:32 UTC · cite as "Nexqual, Faeth Therapeutics, Inc. (FTH), nexqual.com/FTH" · informational, not investment advice.

**Price:** USD 20.22 (+5.31% today) · US market open, as of October 29, 2026 at 15:32 UTC; quotes may be delayed. Prev close 19.2 · day 19.23–20.33 · 52w 7.45–42.14 · market cap $522M · NCM

## Key facts
- Insider open-market sales, last ~7 months: 5 Form 4 filings, $1.7M; 5 not under a Rule 10b5-1 plan ($1.7M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 7 Form 4 filings, $2.5M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.81 on a 1–5 scale) (16 analysts), mean target USD 55.38 (range 40–70).
- Total return with dividends: 1Y +115.7% vs S&P 500 +13.2%; 5Y -88.4% vs S&P 500 +79.2%.
- Next earnings: 2026-11-03, EPS estimate USD -0.72, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$37.5M | -$50.2M | -$37.1M | -$32.6M | -$22.3M | -$199M |
| Net income | -$36.8M | -$48.6M | -$34.1M | -$30.2M | -$21.1M | -$196M |
| EPS (diluted) | -$26.60 | -$31.60 | -$24.40 | -$24.01 | -$16.72 | — |
| Free cash flow | -$32.3M | -$39.3M | -$32.2M | -$24.8M | -$20.5M | -$33.9M |
| Cash + short-term investments | $148M | $107M | $65.8M | $41.3M | $21.2M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 3.0x · FCF yield -6.48% · Earnings yield -37.42%

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Cambrian Biopharma Inc |  | 25,000 | $501K | 16.1% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-01 | Peyer James |  | 25,000 | $501K | 16.1% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-02…2026-04-07 | Millennium Management Llc |  | 17,076 | $538K | 11.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-03-31…2026-04-01 | Millennium Management Llc |  | 2,741 | $77K | 1.8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-03-26…2026-03-30 | Millennium Management Llc |  | 3,250 | $89K | 2.2% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
7 purchases, $2.5M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-29…2026-07-01 | Stephenson Brian C | Chief Financial Officer | 13,634 | $326K | 23.92 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-24…2026-06-26 | Stephenson Brian C | Chief Financial Officer | 15,641 | $401K | 25.65 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22…2026-06-23 | Stephenson Brian C | Chief Financial Officer | 17,413 | $406K | 23.31 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22 | Parikh Anand Kiran | President and CEO | 2,806 | $55K | 19.76 | Too little history (no open-market trades in 2023–2025) |
| 2026-04-02…2026-04-07 | Millennium Management Llc |  | 4,215 | $141K | 33.54 | Too little history (no open-market trades in 2023–2025) |
| 2026-03-31…2026-04-01 | Millennium Management Llc |  | 12,180 | $382K | 31.37 | Too little history (no open-market trades in 2023–2025) |
| 2026-03-26…2026-03-30 | Millennium Management Llc |  | 30,585 | $818K | 26.75 | Too little history (no open-market trades in 2023–2025) |

## Analysts
Consensus Buy (mean 1.81 on a 1–5 scale), 16 analysts; mean target USD 55.38 (low 40, high 70).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-27 | BTIG | Reiterated | Buy | $55 |
| 2026-10-16 | William Blair | Initiated | Outperform |  |
| 2026-09-16 | Guggenheim | Initiated | Buy | $70 |
| 2026-09-14 | LUCID CAPITAL MARKETS | Initiated | Buy | $59 |
| 2026-09-09 | TD Cowen | Initiated | Buy |  |
| 2026-08-21 | Needham | Initiated | Buy | $56 |
| 2026-08-11 | HC Wainwright & Co. | Reiterated | Buy | $60 |
| 2026-08-04 | Jones Trading | Initiated | Buy | $55 |
| 2026-07-31 | Raymond James | Initiated | Outperform | $56 |
| 2026-07-28 | Oppenheimer | Initiated | Outperform | $60 |
| 2026-07-20 | Citizens | Initiated | Market Outperform | $51 |
| 2026-07-16 | BTIG | Reiterated | Buy | $55 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +115.7% | -88.4% |
| S&P 500 (SPY) | +13.2% | +79.2% |
| Per year | +115.8% | -34.9% |
| Volatility (annualized) | 154.0% | 107.9% |
| Max drawdown | -69.2% (Feb 2026→Jun 2026) | -97.0% (Nov 2021→Mar 2025) |

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 97.24 +1.32% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.23 -0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.66 -34.81% · IONS (Ionis Pharmaceuticals, Inc.) USD 45.37 +1.05% · AXSM (Axsome Therapeutics, Inc.) USD 143.35 -0.11% · ABVX (Abivax SA) USD 91.02 +1.31%

## More
Full page: https://nexqual.com/FTH · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in FTH's own 10-K filed 2026-03-30 (https://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/snse-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | TAKEDA PHARMACEUTICAL CO LTD (TAK) | "We are party to a license agreement with Takeda that was originally entered into in March 2019, or the Takeda License Agreement, between Takeda and Petra Pharma Corporation, or Petra, which was subsequently assigned by P…" |
| Partner | Adimab | "On July 14, 2021, we entered into a First Amended and Restated Collaboration Agreement, or the Adimab Agreement, with Adimab, LLC, or Adimab." |

## Company outlook (8-K filed 2026-08-04)

- "We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer, which is expected by year-end." Mr."
- "PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), with topline data anticipated in the second half of 2026."
- "PIKTOR is also being evaluated in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.71 | $0.00 | −$0.71 | $0 | 2 |
| Next quarter (ends 2026-12-31) | $-0.79 | $0.00 | −$0.79 | $0 | 2 |
| Current fiscal year (ends 2026-12-31) | $-9.97 | $0.00 | −$9.97 | $0 | 3 |
| Next fiscal year (ends 2027-12-31) | $-3.67 | $0.00 | −$3.67 | $0 | 3 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$2.84 | −$4.76 | Beat +40.3% | — |
| — | Quarter ended Mar 31, 2026 | −$131.45 | −$0.62 | Miss −21101.6% | — |
| — | Quarter ended Dec 31, 2025 | −$3.74 | −$4.81 | Beat +22.2% | — |
| — | Quarter ended Sep 30, 2025 | −$3.62 | −$4.11 | Beat +11.9% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-27 | 8-K | Director or executive officer change, or pay arrangement — “On October 23, 2026, the Board of Directors (the "Board") of Faeth Therapeutics, Inc. (the "Company") increased the size of the Board from six to seven directors and appointed Adam Schayowitz to serve as a Class III director, effective immediately. Dr. Schayowitz will hold office until the Company's 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation or removal. Adam Schayowitz, Ph.D. (age 46) has served as Executive Vice President and Head…” | https://www.sec.gov/Archives/edgar/data/1829802/000119312526432688/0001193125-26-432688-index.htm |
| 2026-09-17 | 8-K | Director or executive officer change, or pay arrangement — “On September 11, 2026, the Board of Directors (the "Board") of Faeth Therapeutics, Inc. (the "Company") increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately. Dr. Vousden will hold office until the Company's 2029 annual meeting of stockholders and until her successor is duly elected and qualified, or her earlier death, resignation or removal. Dr. Vousden was also appointed to serve as a member of the Compensation…” | https://www.sec.gov/Archives/edgar/data/1829802/000119312526394360/0001193125-26-394360-index.htm |
| 2026-08-14 | Schedule 13G/A | Caligan Partners LP, David Johnson: 2.4% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1829802/000172749226000018/0001727492-26-000018-index.htm |
| 2026-08-14 | Schedule 13G/A | Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP: 2.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1829802/000149315226038381/0001493152-26-038381-index.htm |
| 2026-08-14 | Schedule 13G | Khosla Ventures VI, LP, Khosla Ventures Seed D, LP: 10.2% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1829802/000119312526352288/0001193125-26-352288-index.htm |
| 2026-08-14 | Schedule 13G/A | StemPoint Capital LP, StemPoint Capital Management GP LLC: 0.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1829802/000110465926096753/0001104659-26-096753-index.htm |
| 2026-08-04 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1829802/000119312526331562/0001193125-26-331562-index.htm |
| 2026-08-04 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/0001193125-26-331563-index.htm |
| 2026-07-23 | 8-K | Director or executive officer change, or pay arrangement — “On July 21, 2026, the Board of Directors (the "Board") of Faeth Therapeutics, Inc. (the "Company"), upon the recommendation of the Compensation Committee of the Board (the "Compensation Committee"), approved one-time supplemental grants of performance-based stock options ("Performance Options") under the Company's 2026 Equity Incentive Plan (the "2026 Plan") to current employees of the Company who were employed with the Company as of February 19, 2026, including the following: Name Title Option to Purchase Shares…” | https://www.sec.gov/Archives/edgar/data/1829802/000119312526314591/0001193125-26-314591-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.